Sanofi-Aventis and Nichi-Iko lay out plans for new Japanese generics venture
This article was originally published in Scrip
Sanofi-Aventis chose Nichi-Iko as its partner for entering the generics sector in Japan as it was attracted by the company's strong business growth, market presence, entrepreneurial spirit and know-how.
You may also be interested in...
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.